首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1616824

按產品、技術、適應症、應用、地區、範圍和預測劃分的全球免疫腫瘤檢測市場規模

Global Immuno Oncology Assays Market Size By Product, By Technology (Polymerase Chain Reaction, Flow Cytometry), By Indication, By Application, By Geographic Scope and Forecast, By Geographic Scope and Forecast

出版日期: 2024年11月03日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

免疫腫瘤學檢測市場規模及預測

2024 年免疫腫瘤檢測市場規模為 38.7 億美元，預計到 2031 年將達到 57.8 億美元，2024 年至 2031 年複合年增長率為 5.70%。全球免疫腫瘤學測試是指一系列旨在評估對癌症的免疫反應並評估免疫療法治療效果的診斷測試。這些測試對於識別免疫檢查點抑制劑和腫瘤浸潤淋巴細胞等特定生物標記至關重要，這有助於為癌症患者制定個人化治療計劃。免疫腫瘤學檢測的應用涵蓋多種癌症類型，有助於指導臨床決策、監測治療反應和預測患者結果。

隨著生物標記發現、新一代定序技術的進步以及免疫治療研究投資的增加，該領域的未來充滿希望。隨著個人化癌症治療需求的增加，提高癌症治療的精確度並提高患者存活率，全球免疫腫瘤檢測市場預計將顯著擴大。

免疫腫瘤學檢測的全球市場動態

塑造全球免疫腫瘤檢測市場的關鍵市場動態

主要市場驅動因子

癌症發生率增加：

全球癌症發生率的增加是免疫腫瘤檢測市場的關鍵推動因素。據世界衛生組織 (WHO) 稱，受癌症影響的人數預計將從 2020 年的 1930 萬人增加到 2040 年的 2950 萬人。癌症發生率的快速增加推動了對有效診斷工具的需求，包括免疫腫瘤學檢測。

免疫療法的流行使用：

免疫療法在癌症治療中的普及和成功正在推動市場發展。美國癌症協會報告稱，近年來批准的新癌症治療方法中約有 50% 是免疫療法，這凸顯了需要能夠識別這些治療方法的合適候選藥物的檢測方法。

生物標記發現的進展：

生物標記研究和技術的創新正在推動免疫腫瘤學檢測的發展。美國國立衛生研究院 (NIH) 報告稱，從 2021 年到 2022 年，癌症生物標記的研究經費將增加 17%，旨在提高檢測準確性並提高其預測治療效果的有效性的研究正在推進。

增加政府資助和支持：

各國政府正在增加對癌症研究和免疫療法開發的投資，加強免疫腫瘤學檢測市場。例如，美國國家癌症研究所（NCI）已在2023年撥款約60億美元用於癌症研究，其中大部分用於免疫療法和相關診斷技術的開發。

主要挑戰

檢測成本高：

先進的免疫腫瘤學檢測的開發和實施成本高昂，某些醫療機構和患者的使用可能受到限制。高成本也可能阻礙廣泛採用，特別是在預算限制令人擔憂的發展中地區。

監理障礙：

瞭解免疫腫瘤學檢測的監管環境既複雜又耗時。臨床驗證和批准的嚴格監管要求可能會延遲新檢測方法的市場推出，並影響患者及時獲得創新診斷。

資料解釋的複雜性：

由於免疫反應和腫瘤生物學的複雜性，解釋免疫腫瘤學檢測的結果可能很困難。臨床醫生可能需要專門的培訓才能準確解釋結果，這使得將這些測試融入日常臨床實踐變得複雜。

標準化有限：

不同免疫腫瘤學檢測之間缺乏標準化可能會導致結果和結局的差異。這種差異使臨床醫生很難比較結果，並使監管審批過程更加複雜。

主要趨勢：

人工智慧 (AI) 與機器學習的整合：

人工智慧和機器學習在免疫腫瘤學檢測數據分析的應用正在迅速普及。這些技術可以增強數據解釋、識別模式並提高治療效果預測的準確性，最終改善患者的治療結果。

個人化醫療重點：

隨著對個人化醫療的日益重視，免疫腫瘤學檢測在根據腫瘤特徵和免疫特徵為個別患者定制治療方面發揮著重要作用。預計這一趨勢將推動對更複雜和更精確檢測的需求。

夥伴關係與聯合研究：

生技公司、研究機構和醫療保健提供者之間的合作夥伴關係正在不斷加強，以促進免疫腫瘤學檢測的創新。這些合作夥伴關係旨在彙集專業知識和資源，以有效開發新的診斷工具並將其商業化。

進入新興市場：

隨著醫療保健基礎設施的改善和癌症治療意識的提高，免疫腫瘤學測試市場正在擴展到新興市場。對於希望向傳統服務欠缺地區擴張的公司來說，這一趨勢代表著一個重大的成長機會。

Immuno Oncology Assays Market size was valued at USD 3.87 Billion in 2024 and is projected to reach USD 5.78 Billion by 2031 , growing at a CAGR of 5.70% from 2024 to 2031. Global immuno-oncology assays refer to a range of diagnostic tests designed to evaluate the immune response to cancer and assess the effectiveness of immunotherapy treatments. These assays are crucial for identifying specific biomarkers, such as immune checkpoint inhibitors and tumor-infiltrating lymphocytes, which help tailor personalized treatment plans for cancer patients. The applications of immuno-oncology assays extend across various cancer types, guiding clinical decision-making, monitoring treatment responses, and predicting patient outcomes.

The future of this field looks promising, driven by advancements in biomarker discovery, next-generation sequencing technologies, and increasing investments in immunotherapy research. As the demand for personalized cancer treatment grows, the global immuno-oncology assays market is expected to expand significantly, enhancing the precision of cancer therapies and improving patient survival rates.

Global Immuno Oncology Assays Market Dynamics

The key market dynamics that are shaping the global immuno-oncology assays market include:

Key Market Drivers:

Rising Incidence of Cancer:

The increasing prevalence of cancer worldwide is a significant driver for the immuno-oncology assays market. According to the World Health Organization (WHO), cancer cases are expected to rise to 29.5 million globally by 2040, up from 19.3 million in 2020. This surge in cancer incidence is driving the demand for effective diagnostic tools, including immuno-oncology assays.

Growing Adoption of Immunotherapy:

The rising acceptance and success of immunotherapy in cancer treatment are propelling the market. A report by the American Cancer Society states that approximately 50% of new cancer drugs approved in recent years are immunotherapies, highlighting the need for assays that can identify suitable candidates for these treatments.

Advancements in Biomarker Discovery:

Innovations in biomarker research and technology are enhancing the development of immuno-oncology assays. The National Institutes of Health (NIH) reported a 17% increase in research funding for cancer biomarkers between 2021 and 2022, driving advancements that improve assay accuracy and effectiveness in predicting treatment responses.

Increased Government Funding and Support:

Governments are increasingly investing in cancer research and immunotherapy development, which bolsters the immuno-oncology assays market. For instance, the National Cancer Institute (NCI) in the U.S. allocated approximately $6 billion for cancer research in 2023, with a significant portion dedicated to advancing immunotherapy and related diagnostic technologies.

Key Challenges:

High Cost of Assays:

The development and implementation of advanced immuno-oncology assays can be expensive, which may limit access for some healthcare facilities and patients. High costs can also hinder widespread adoption, especially in developing regions where budget constraints are a concern.

Regulatory Hurdles:

Navigating the regulatory landscape for immuno-oncology assays can be complex and time-consuming. Stringent regulatory requirements for clinical validation and approval may delay the introduction of new assays into the market, impacting timely patient access to innovative diagnostics.

Data Interpretation Complexity:

The interpretation of results from immuno-oncology assays can be challenging due to the complexity of immune responses and tumor biology. Clinicians may require specialized training to accurately interpret the results, which can complicate the integration of these assays into routine clinical practice.

Limited Standardization:

There is a lack of standardization across different immuno-oncology assays, which can lead to variability in results and outcomes. This inconsistency makes it difficult for clinicians to compare results and makes regulatory approval processes more complicated.

Key Trends:

Integration of Artificial Intelligence (AI) and Machine Learning:

The use of AI and machine learning in the analysis of immuno-oncology assay data is gaining traction. These technologies can enhance data interpretation, identify patterns, and improve the accuracy of predictions related to treatment responses, ultimately leading to better patient outcomes.

Personalized Medicine Focus:

There is a growing emphasis on personalized medicine, with immuno-oncology assays playing a crucial role in tailoring treatments to individual patients based on their specific tumor characteristics and immune profiles. This trend is expected to drive the demand for more sophisticated and precise assays.

Partnerships and Collaborations:

Increasing collaborations between biotechnology companies, research institutions, and healthcare providers are emerging to foster innovation in immuno-oncology assays. These partnerships aim to combine expertise and resources to develop and commercialize new diagnostic tools effectively.

Expansion into Emerging Markets:

The immuno-oncology assays market is witnessing expansion into emerging markets as healthcare infrastructure improves and awareness of cancer treatments increases. This trend presents significant growth opportunities for companies looking to tap into previously underserved regions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Immuno Oncology Assays Market Regional Analysis

Here is a more detailed regional analysis of the global immuno oncology assays market:

North America:

North America holds a dominant position in the Immuno-Oncology Assays market, primarily driven by the advanced healthcare infrastructure, significant investments in cancer research, and a high prevalence of cancer cases. The region is home to leading pharmaceutical and biotechnology companies that are actively engaged in the development of innovative immuno-oncology therapies. According to the National Cancer Institute (NCI), an estimated 1.9 million new cancer cases will be diagnosed in the U.S. in 2024, which underscores the urgent need for effective diagnostic and treatment options.

Additionally, the regulatory environment in North America, particularly in the United States, is supportive of rapid innovations in cancer diagnostics and therapeutics. The U.S. Food and Drug Administration (FDA) has expedited the approval process for immuno-oncology assays, facilitating quicker access to market. This regulatory advantage, combined with high healthcare spending per capita, enhances the region's leadership in the immuno-oncology assays market.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for Immuno-Oncology Assays, fueled by a rising incidence of cancer and increasing healthcare expenditure. The region is witnessing a surge in cancer cases due to factors such as an aging population and lifestyle changes, making the development and implementation of immuno-oncology therapies critical. According to the World Health Organization (WHO), cancer cases in Asia are projected to reach over 7.1 million by 2030, highlighting a significant demand for advanced diagnostic tools and treatments.

Governments in countries like China, Japan, and India are investing heavily in cancer research and healthcare infrastructure to combat the rising cancer burden. For instance, the Chinese government allocated approximately $2.5 billion for cancer research in its latest five-year plan, which aims to improve cancer detection and treatment. This commitment is expected to accelerate the adoption of immuno-oncology assays in the region.

Global Immuno Oncology Assays Market: Segmentation Analysis

The Global Immuno Oncology Assays Market is segmented on the basis of Product, Application, Indication, Technology, and Geography.

Immuno Oncology Assays Market, By Product

Consumables
Software and Services
Instruments

Based on Product, the Global Immuno Oncology Assays Market is segmented into Consumables, Software and Services, and Instruments. The Consumables segment is currently dominating due to the recurring need for reagents, kits, and other consumables required for conducting assays. Conversely, the Software and Services segment is the fastest-growing, driven by the increasing demand for advanced data analysis and interpretation tools, as well as the rising adoption of integrated solutions that enhance laboratory efficiency.

Immuno Oncology Assays Market, By Application

Research Applications
Clinical Diagnostics

Based on Application, the Global Immuno Oncology Assays Market is segmented into Research Applications and Clinical Diagnostics. The Research Applications segment is currently dominating, driven by significant investments in cancer research and development initiatives aimed at discovering new biomarkers and therapies. However, the Clinical Diagnostics segment is the fastest-growing, fueled by the increasing adoption of immunotherapy in clinical settings and the demand for personalized treatment strategies.

Immuno Oncology Assays Market, By Indication

Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma

Based on Indication, the Global Immuno Oncology Assays Market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer and Melanoma. The Lung Cancer segment currently dominates due to the high prevalence of the disease and the significant advancements in immunotherapy options for lung cancer patients. Conversely, the Melanoma segment is the fastest-growing, fueled by the increasing incidence of melanoma and the rapid development of innovative immunotherapies, such as immune checkpoint inhibitors, which have shown promising results in clinical trials.

Immuno Oncology Assays Market, By Technology

Polymerase Chain Reaction (PCR)
Flow Cytometry
Immunoassay
Next-Generation Sequencing (NGS)
In Situ Hybridization (ISH)

Based on Application, the Global Immuno Oncology Assays Market is segmented into Polymerase Chain Reaction (PCR), Flow Cytometry, Immunoassay, Next-Generation Sequencing (NGS), and In Situ Hybridization (ISH). The Polymerase Chain Reaction (PCR) segment currently dominates due to its widespread use in detecting and amplifying specific DNA sequences, making it essential for various diagnostic applications in oncology. Conversely, the Next-Generation Sequencing (NGS) segment is the fastest-growing, driven by advancements in sequencing technologies and their capacity to analyze multiple genes simultaneously.

Immuno Oncology Assays Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on the Geography, the Global Immuno Oncology Assays Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America holds a dominant position in the Immuno-Oncology Assays market, primarily driven by the advanced healthcare infrastructure, significant investments in cancer research, and a high prevalence of cancer cases. The Asia Pacific region is the fastest-growing market for Immuno-Oncology Assays, fueled by a rising incidence of cancer and increasing healthcare expenditure.

Key Players

The "Global Immuno Oncology Assays Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Agilent Technologies, Inc., PerkinElmer, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Crown Bioscience Inc., Merck & Company, Inc., InSphero Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc.
Our
market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Global Immuno Oncology Assays Market: Recent Developments
In August 2024 Roche received U.S. Food and Drug Administration (FDA) approval for its new companion diagnostic assay that supports the use of a targeted therapy for breast cancer patients. This assay is designed to identify patients who are most likely to benefit from specific immuno-oncology treatments, thereby streamlining the patient selection process and improving treatment efficacy.
In July 2024 Thermo Fisher Scientific announced an expansion of its immuno-oncology portfolio with the introduction of new assays for tumor microenvironment analysis. These assays are designed to provide comprehensive insights into tumor behavior and immune response, supporting researchers in their quest to develop more effective immunotherapies. The company aims to enhance its leadership in precision medicine with these innovative solutions.
In June 2024 Agilent Technologies announced a partnership with leading academic institutions to develop novel immuno-oncology assays. This collaboration aims to accelerate research in tumor immunology and biomarker discovery, fostering innovation in the field. Agilent's CEO highlighted the importance of collaborative efforts in advancing immuno-oncology research and improving patient care through novel diagnostic solutions.

1 INTRODUCTION OF GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY PRODUCT

5.1 Overview
5.2 Consumables
5.3 Software and Services
5.4 Instruments

6 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY APPLICATION

6.1 Overview
6.2 Research Applications
6.3 Clinical Diagnostics

7 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY INDICATION

7.1 Overview
7.2 Lung Cancer
7.3 Breast Cancer
7.4 Colorectal Cancer
7.5 Bladder Cancer
7.6 Melanoma
7.7 Other Cancers

8 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY

8.1 Overview
8.2 Polymerase Chain Reaction (PCR)
8.3 Flow Cytometry
8.4 Immunoassay
8.5 Next-Generation Sequencing (NGS)
8.6 In Situ Hybridization (ISH)

9 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Agilent Technologies, Inc.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Thermo Fisher Scientific, Inc.
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 PerkinElmer, Inc.
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Illumina, Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 PerkinElmer, Inc.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Crown Bioscience Inc.
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Development
11.7 InSphero, Inc.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Merck & Company, Inc.
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 F.Hoffmann-La Roche Ltd.
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Development
11.10 HTG Molecular Diagnostics, Inc.
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Development